Best卵黄样黄斑营养不良自然病史研究报告1:临床特征与遗传发现
该单中心回顾性连续观察性研究纳入222例携带BEST1基因致病性单等位序列变异的Best卵黄样黄斑营养不良(BVMD)患者,分析其遗传发现、临床谱系与自然病史。结果显示BVMD表型变异广泛、进展非常缓慢,平均随访9.7年间最佳矫正视力(BCVA)年丢失率右眼0.013 logMAR、左眼0.009 logMAR。p.(Ala243Val)变异较p.(Arg218Cys)和p.(Arg218His)发病年龄更晚、年龄校正BCVA更好、Gass分期更轻。
要点
- 222例BVMD患者来自141个家系,共检出69种BEST1变异,平均就诊年龄26.8岁。
- 平均随访9.7年间BCVA年丢失率右眼0.013 logMAR、左眼0.009 logMAR,疾病进展非常缓慢。
- 37例(17.3%)在平均8.0年随访中诊断脉络膜新生血管(CNV),接受抗VEGF治疗眼平均BCVA优于未治疗眼。
核心结论
- BVMD表型变异广泛,疾病进展非常缓慢,观察到的表型-基因型关联有助于更准确地预后判断和遗传咨询。
研究设计与样本
- 单中心回顾性、连续、观察性研究,纳入222名儿童和成人患者,来自141个家系,均携带BEST1基因可能致病性单等位序列变异。
- 数据提取自电子和纸质病例记录,分析电生理评估和分子遗传学检测结果。
主要发现
- 共222例患者来自141个家系,检出69种BEST1变异;平均就诊年龄26.8岁(范围1.3-84.8岁),61.5%的患者中心视力恶化。
- 主要眼底表现包括黄白色卵黄样病灶128眼(30.6%)、萎缩性改变78眼(18.7%)、纤维化改变49眼(11.7%)、轻度色素改变48眼(11.5%)、卵黄破裂外观43眼(10.3%)。
- 就诊时平均BCVA右眼0.37 logMAR(Snellen等效20/47)、左眼0.33 logMAR(Snellen等效20/43),平均随访9.7年间年丢失率分别为0.013 logMAR和0.009 logMAR。
- 37例患者(17.3%)在平均8.0年随访中诊断CNV;接受抗VEGF治疗的CNV眼平均BCVA为0.28 logMAR(Snellen等效20/38),未接受抗VEGF治疗眼为0.62 logMAR(Snellen等效20/83)。
- 多数眼(78.7%)表现为远视性屈光不正,13例患者(6.1%)诊断弱视;3种最常见变异中,p.(Ala243Val)较p.(Arg218Cys)和p.(Arg218His)与更晚发病年龄、更好的年龄校正BCVA及更轻的Gass分期相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze the genetic findings, clinical spectrum, and natural history of Best vitelliform macular dystrophy (BVMD) in a cohort of 222 children and adults. DESIGN: Single-center retrospective, consecutive, observational study. PARTICIPANTS: Patients with a clinical diagnosis of BVMD from pedigrees with a likely disease-causing monoallelic sequence variant in the BEST1 gene. METHODS: Data were extracted from electronic and physical case notes. Electrophysiologic assessment and molecular genetic testing were analyzed. MAIN OUTCOME MEASURES: Molecular genetic test findings and clinical findings including best-corrected visual acuity (BCVA), choroidal neovascularization (CNV) rates, and electrophysiologic parameters. RESULTS: Two hundred twenty-two patients from 141 families were identified harboring 69 BEST1 variants. Mean age at presentation was 26.8 years (range, 1.3-84.8 years) and most patients (61.5%) demonstrated deterioration of central vision. Major funduscopic findings included 128 eyes (30.6%) with yellow vitelliform lesions, 78 eyes (18.7%) with atrophic changes, 49 eyes (11.7%) with fibrotic changes, 48 eyes (11.5%) with mild pigmentary changes, and 43 eyes (10.3%) showing a vitelliruptive appearance. Mean BCVA was 0.37 logarithm of the minimum angle of resolution (logMAR; Snellen equivalent, 20/47) for the right eye and 0.33 logMAR (Snellen equivalent, 20/43) for the left eye at presentation, with a mean annual loss rate of 0.013 logMAR and 0.009 logMAR, respectively, over a mean follow-up of 9.7 years. Thirty-seven patients (17.3%) received a diagnosis of CNV over a mean follow-up of 8.0 years. Eyes with CNV that received treatment with an anti-vascular endothelial growth factor (VEGF) agent showed better mean BCVA compared with eyes that were not treated with an anti-VEGF agent (0.28 logMAR [Snellen equivalent, 20/38] vs. 0.62 logMAR [Snellen equivalent, 20/83]). Most eyes exhibited a hyperopic refractive error (78.7%), and 13 patients (6.1%) received a diagnosis of amblyopia. Among the 3 most common variants, p.(Ala243Val) was associated with a later age of onset, better age-adjusted BCVA, and less advanced Gass stages compared with p.(Arg218Cys) and p.(Arg218His). CONCLUSIONS: BVMD shows a wide spectrum of phenotypic variability. The disease is very slowly progressive, and the observed phenotype-genotype correlations allow for more accurate prognostication and counselling. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Laich Y, Georgiou M, Fujinami K, et al. Best Vitelliform Macular Dystrophy Natural History Study Report 1: Clinical Features and Genetic Findings. Ophthalmology. 2024. PMID: 38278445. doi:10.1016/j.ophtha.2024.01.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。